Haemonetics Corporation

Symbol: HAE

NYSE

92.6

USD

Market price today

  • 37.1413

    P/E Ratio

  • 0.2223

    PEG Ratio

  • 4.70B

    MRK Cap

  • 0.00%

    DIV Yield

Haemonetics Corporation (HAE) Stock Price & Analysis

Shares Outstanding

50.79M

Gross Profit Margin

0.53%

Operating Profit Margin

0.13%

Net Profit Margin

0.10%

Return on Assets

0.06%

Return on Equity

0.14%

Return on Capital Employed

0.09%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO:Mr. Christopher A. Simon
Full-time employees:3034
City:Boston
Address:125 Summer Street
IPO:1991-05-10
CIK:0000313143

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

General Outlook

In simple terms, Haemonetics Corporation has 50.786 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.529% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.134%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.100%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.058% return, is a testament to Haemonetics Corporation's adeptness in optimizing resource deployment. Haemonetics Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.144%. Furthermore, the proficiency of Haemonetics Corporation in capital utilization is underscored by a remarkable 0.088% return on capital employed.

Stock Prices

Haemonetics Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $93.86, while its low point bottomed out at $91.48. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Haemonetics Corporation's stock market.

Liquidity Ratios

Analyzing HAE liquidity ratios reveals its financial health of the firm. The current ratio of 292.25% gauges short-term asset coverage for liabilities. The quick ratio (155.39%) assesses immediate liquidity, while the cash ratio (74.11%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio292.25%
Quick Ratio155.39%
Cash Ratio74.11%

Profitability Ratios

HAE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 12.68% underscores its earnings before tax deductions. The effective tax rate stands at 21.42%, revealing its tax efficiency. The net income per EBT, 78.58%, and the EBT per EBIT, 94.64%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 13.40%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin12.68%
Effective Tax Rate21.42%
Net Income per EBT78.58%
EBT per EBIT94.64%
EBIT per Revenue13.40%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.92, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 600.24% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding155
Days of Inventory Outstanding185
Operating Cycle246.29
Days of Payables Outstanding35
Cash Conversion Cycle212
Receivables Turnover6.00
Payables Turnover10.52
Inventory Turnover1.97
Fixed Asset Turnover3.99
Asset Turnover0.58

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 3.89, and free cash flow per share, 2.54, depict cash generation on a per-share basis. The cash per share value, 3.84, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.16, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share3.89
Free Cash Flow per Share2.54
Cash per Share3.84
Operating Cash Flow Sales Ratio0.16
Free Cash Flow to Operating Cash Flow Ratio0.65
Cash Flow Coverage Ratio0.23
Short Term Coverage Ratio14.36
Capital Expenditure Coverage Ratio2.88
Dividend Paid and Capex Coverage Ratio2.88

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 39.56%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.92, we discern the balance between debt and equity financing. The long-term debt to capitalization, 47.60%, and total debt to capitalization, 48.00%, ratios shed light on its capital structure. An interest coverage of 18.67 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio39.56%
Debt Equity Ratio0.92
Long Term Debt to Capitalization47.60%
Total Debt to Capitalization48.00%
Interest Coverage18.67
Cash Flow to Debt Ratio0.23
Company Equity Multiplier2.33

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 23.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, 2.27, reflects the portion of profit attributed to each share. The book value per share, 16.11, represents the net asset value distributed per share, while the tangible book value per share, 1.50, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share23.01
Net Income Per Share2.27
Book Value Per Share16.11
Tangible Book Value Per Share1.50
Shareholders Equity Per Share16.11
Interest Debt Per Share15.37
Capex Per Share-2.17

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 17.67%, indicates top-line expansion, while the gross profit growth, 21.68%, reveals profitability trends. EBIT growth, 93.23%, and operating income growth, 93.23%, offer insights into operational profitability progression. The net income growth, 166.05%, showcases bottom-line expansion, and the EPS growth, 167.06%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth17.67%
Gross Profit Growth21.68%
EBIT Growth93.23%
Operating Income Growth93.23%
Net Income Growth166.05%
EPS Growth167.06%
EPS Diluted Growth166.67%
Weighted Average Shares Growth-0.52%
Weighted Average Shares Diluted Growth0.13%
Operating Cash Flow Growth58.51%
Free Cash Flow Growth114.99%
10-Year Revenue Growth per Share32.48%
5-Year Revenue Growth per Share34.31%
3-Year Revenue Growth per Share18.02%
10-Year Operating CF Growth per Share224.54%
5-Year Operating CF Growth per Share28.73%
3-Year Operating CF Growth per Share72.28%
10-Year Net Income Growth per Share200.74%
5-Year Net Income Growth per Share163.06%
3-Year Net Income Growth per Share50.53%
10-Year Shareholders Equity Growth per Share7.53%
5-Year Shareholders Equity Growth per Share12.94%
3-Year Shareholders Equity Growth per Share39.08%
Receivables Growth12.40%
Inventory Growth-11.48%
Asset Growth4.04%
Book Value per Share Growth9.72%
Debt Growth-1.00%
R&D Expense Growth7.12%
SGA Expenses Growth10.93%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 4,683,713,250, captures the company's total value, considering both debt and equity. Income quality, 2.37, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.32, gauges operational efficiency, while the research and development to revenue, 4.29%, highlights investment in innovation. The ratio of intangibles to total assets, 38.35%, indicates the value of non-physical assets, and capex to operating cash flow, -40.35%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value4,683,713,250
Income Quality2.37
Sales General and Administrative to Revenue0.32
Research and Development to Revenue4.29%
Intangibles to Total Assets38.35%
Capex to Operating Cash Flow-40.35%
Capex to Revenue-9.43%
Capex to Depreciation-118.10%
Stock-Based Compensation to Revenue2.19%
Graham Number28.70
Return on Tangible Assets9.67%
Graham Net Net-11.17
Working Capital517,906,000
Tangible Asset Value75,995,000
Net Current Asset Value-347,106,000
Invested Capital1
Average Receivables169,259,000
Average Payables61,150,000
Average Inventory276,203,000
Days Sales Outstanding56
Days Payables Outstanding42
Days of Inventory On Hand171
ROIC8.04%
ROE0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.98, and the price to book ratio, 4.98, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.70, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 36.53, and price to operating cash flows, 23.83, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.98
Price to Book Ratio4.98
Price to Sales Ratio3.70
Price Cash Flow Ratio23.83
Price Earnings to Growth Ratio0.22
Enterprise Value Multiple15.59
Price Fair Value4.98
Price to Operating Cash Flow Ratio23.83
Price to Free Cash Flows Ratio36.53
Price to Tangible Book Ratio5.14
Enterprise Value to Sales4.01
Enterprise Value Over EBITDA18.78
EV to Operating Cash Flow17.15
Earnings Yield2.75%
Free Cash Flow Yield3.88%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Haemonetics Corporation (HAE) on the NYSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 37.141 in 2024.

What is the ticker symbol of Haemonetics Corporation stock?

The ticker symbol of Haemonetics Corporation stock is HAE.

What is company IPO date?

IPO date of Haemonetics Corporation is 1991-05-10.

What is company current share price?

Current share price is 92.600 USD.

What is stock market cap today?

The market cap of stock today is 4702792860.000.

What is PEG ratio in 2024?

The current 0.222 is 0.222 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3034.